Overview

This is a summary of the European public assessment report (EPAR) for Actrapid. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Actrapid.

Actrapid is a solution for injection that contains the active substance human insulin. It is available as vials, cartridges (Penfill) or prefilled pens (NovoLet, InnoLet or FlexPen).

Actrapid is used to treat diabetes.

The medicine can only be obtained with a prescription.

Actrapid is given by injection under the skin in the thigh, the abdominal wall (at the front of the waist), the deltoid region (shoulder) or the gluteal region (buttocks). The patient's blood glucose (sugar) should be tested regularly to find the lowest effective dose.

The usual dose is between 0.3 and 1.0 international units (IU) per kilogram body weight per day. Actrapid is given 30 minutes before a meal. Actrapid is a fast-acting insulin and may be used with intermediate or long-acting insulins. Actrapid may also be given intravenously (into a vein) but only by a doctor or a nurse.

Diabetes is a disease in which the body does not produce enough insulin to control the blood glucose or when the body is unable to use insulin effectively. Actrapid is a replacement insulin that is very similar to the insulin made by the pancreas.

The active substance in Actrapid, human insulin, is produced by a method known as ‘recombinant technology’: the insulin is made by a yeast that has received a gene (DNA), which makes it able to produce insulin. The replacement insulin acts in same way as naturally produced insulin and helps glucose enter cells from the blood. By controlling the blood glucose, the symptoms and complications of diabetes are reduced.

Actrapid has been studied in patients with type-1 diabetes,when the pancreas cannot produce insulin (two studies involving 1,954 patients), and type-2 diabetes, when the body is unable to use insulin effectively (one study involving 182 patients). The studies compared Actrapid with another replacement insulin called insulin aspart over six months by measuring the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached. HbA1c gives an indication of how well the blood glucose is controlled.

HbA1c levels remained fairly steady over the six months of treatment with Actrapid.

The most common side effect with Actrapid (seen in more than 1 patient in 10) is hypoglycaemia (low blood glucose levels). For the full description of all side effects reported with Actrapid, see the package leaflet.

Actrapid must not be used in people who are hypersensitive to human insulin or any of the other ingredients.

The CHMP decided that Actrapid’s benefits are greater than its risks and recommended that it be given marketing authorisation.

The European Commission granted a marketing authorisation valid throughout the European Union for Actrapid on 7 October 2002.

For more information about treatment with Actrapid, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Actrapid : EPAR - Summary for the public

български (BG) (99.69 KB - PDF)
español (ES) (72.51 KB - PDF)
čeština (CS) (118.81 KB - PDF)
dansk (DA) (72.49 KB - PDF)
Deutsch (DE) (72.74 KB - PDF)
eesti keel (ET) (71.52 KB - PDF)
ελληνικά (EL) (98.82 KB - PDF)
français (FR) (73.07 KB - PDF)
italiano (IT) (72.11 KB - PDF)
latviešu valoda (LV) (93.91 KB - PDF)
lietuvių kalba (LT) (93.93 KB - PDF)
magyar (HU) (91.9 KB - PDF)
Malti (MT) (97.22 KB - PDF)
Nederlands (NL) (72.18 KB - PDF)
polski (PL) (96.83 KB - PDF)
português (PT) (72.36 KB - PDF)
română (RO) (93.47 KB - PDF)
slovenčina (SK) (117.46 KB - PDF)
slovenščina (SL) (88.01 KB - PDF)
Suomi (FI) (71.47 KB - PDF)
svenska (SV) (65.31 KB - PDF)

Actrapid : EPAR - Risk-management-plan summary

Product information

Actrapid : EPAR - Product Information

български (BG) (1.27 MB - PDF)
español (ES) (1.04 MB - PDF)
čeština (CS) (1.14 MB - PDF)
dansk (DA) (1.05 MB - PDF)
Deutsch (DE) (1.06 MB - PDF)
eesti keel (ET) (1.01 MB - PDF)
ελληνικά (EL) (1.24 MB - PDF)
français (FR) (1.06 MB - PDF)
hrvatski (HR) (1.16 MB - PDF)
íslenska (IS) (1.01 MB - PDF)
italiano (IT) (1.17 MB - PDF)
latviešu valoda (LV) (1.19 MB - PDF)
lietuvių kalba (LT) (1.46 MB - PDF)
magyar (HU) (1.2 MB - PDF)
Malti (MT) (1.07 MB - PDF)
Nederlands (NL) (1.02 MB - PDF)
norsk (NO) (1022.26 KB - PDF)
polski (PL) (1.31 MB - PDF)
português (PT) (1.05 MB - PDF)
română (RO) (1.19 MB - PDF)
slovenčina (SK) (1.18 MB - PDF)
slovenščina (SL) (1.12 MB - PDF)
Suomi (FI) (1.03 MB - PDF)
svenska (SV) (1.02 MB - PDF)

Latest procedure affecting product information: WS/1901

24/09/2020

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Actrapid : EPAR - All Authorised presentations

български (BG) (148.85 KB - PDF)
español (ES) (117.2 KB - PDF)
čeština (CS) (135.25 KB - PDF)
dansk (DA) (121.89 KB - PDF)
Deutsch (DE) (118.68 KB - PDF)
eesti keel (ET) (134.83 KB - PDF)
ελληνικά (EL) (138.26 KB - PDF)
français (FR) (134.78 KB - PDF)
íslenska (IS) (120.52 KB - PDF)
italiano (IT) (116.79 KB - PDF)
latviešu valoda (LV) (139.22 KB - PDF)
lietuvių kalba (LT) (152.2 KB - PDF)
magyar (HU) (157.35 KB - PDF)
Malti (MT) (155.35 KB - PDF)
Nederlands (NL) (114.54 KB - PDF)
norsk (NO) (117.17 KB - PDF)
polski (PL) (153.47 KB - PDF)
português (PT) (117.48 KB - PDF)
română (RO) (147.1 KB - PDF)
slovenčina (SK) (135.83 KB - PDF)
slovenščina (SL) (132.32 KB - PDF)
Suomi (FI) (116.37 KB - PDF)
svenska (SV) (136.24 KB - PDF)

Product details

Name of medicine
Actrapid
Active substance
human insulin
International non-proprietary name (INN) or common name
human insulin (rDNA)
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AB01

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Treatment of diabetes mellitus.

Authorisation details

EMA product number
EMEA/H/C/000424
Marketing authorisation holder
Novo Nordisk A/S

Novo Allé
DK-2880 Bagsvaerd
Denmark

Marketing authorisation issued
07/10/2002
Revision
17

Assessment history

Actrapid : EPAR - Procedural steps taken and scientific information after authorisation

Actrapid : EPAR - Procedural steps taken before authorisation

Actrapid : EPAR - Scientific Discussion

Topics

This page was last updated on

How useful do you find this page?